What is the next step for VX-770 and VX-809 as a combination therapy?
Vertex plans to begin the second part of the Phase 2 trial in the fourth quarter of 2011, following further evaluation of the results from the first part. The study will evaluate the effect of multiple combinations of VX-770 and VX-809 on sweat chloride levels, as well as safety and tolerability. The second part of the trial is also expected to dose VX-770 and VX-809 for a longer period of time than the first part.